trending Market Intelligence /marketintelligence/en/news-insights/trending/sro3EG9PvE3rQVfajdu9rw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Scholar Rock to get $25M milestone award in fibrosis collaboration with Gilead

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Scholar Rock to get $25M milestone award in fibrosis collaboration with Gilead

Scholar Rock Holding Corp. said it will receive a $25 million payment from Gilead Sciences Inc. as part of a collaboration agreement between the companies.

Cambridge, Mass.-based Scholar Rock and Gilead are collaborating to discover and develop treatments for fibrosis, a disease that scars tissues and vital organs and can be fatal.

The milestone payment was triggered by the successful demonstration of efficacy in preclinical studies of selective inhibitors for latent transforming growth factor-beta, or TGF-B, which is activated in fibrotic diseases.

Under the collaboration, Scholar Rock received $80 million up front — $50 million in cash and $30 million investment in Scholar Rock's common shares — from Gilead. In addition to this milestone payment, Scholar Rock is eligible to receive up to an additional $1.43 billion from Gilead on achieving certain development, regulatory and commercial milestones.

Gilead holds the exclusive option to license worldwide rights to products developed as part of Scholar Rock's three TGF-B programs.

Scholar Rock is responsible for the discovery and preclinical research of potential products, while Gilead after exercising its option will conduct preclinical and clinical development as well as commercialization of the selected programs.